June 10, 2026 (View All Issues)
- PSA is a useful tool in the management of prostate cancer; ...
Daraxonrasib Extends Median Survival in Previously Treated Pancreatic Cancer
Median Overall survival was nearly doubled among patients with previously treated metastatic pancreatic cancer who received the multiselective RAS(ON) inhibitor daraxonrasib in the phase III RASolute 302 trial, the results of which were presented at the Plenary Session of the 2026 ASCO Annual...
Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status
Patient-reported outcomes from a subgroup analysis of the final analysis of the phase III PRIMA/ENGOT-OV26/GOG-3012 trial showed that first-line maintenance therapy with the PARP inhibitor niraparib did not adversely affect overall health-related quality of life in patients with newly diagnosed...
After the Founder: What a Cervical Cancer Program in Haiti Teaches About Sustaining Prevention
In 2016, The ASCO Post published an article titled “An Oncologist Battles a Preventable Epidemic: Cancer of the Cervix,” highlighting the work of Robert D. Hilgers, MD—now deceased—and the Women’s Global Cancer Alliance (WGCA) in building a cervical cancer screening and prevention program in...
Adjuvant Selpercatinib Deemed ‘Immediately Practice-Changing’ in Early-Stage RET Fusion–Positive NSCLC
The phase III LIBRETTO-432 trial of adjuvant therapy with the central nervous system (CNS)–penetrant oral RET inhibitor selpercatinib met its primary endpoint of improved event-free survival in patients with early-stage RET fusion–positive non–small cell lung cancer (NSCLC), based on data presented ...
Tafasitamab/Lenalidomide Combination vs R-CHOP in High-Risk DLBCL: Phase III frontMIND Trial
In patients newly diagnosed with high-risk large B-cell lymphoma, the addition of the CD19 monoclonal antibody tafasitamab plus the immunomodulatory drug lenalidomide (Tafa/Len) to standard therapy led to a 25% reduction in the risk of death or progression in the phase III frontMIND trial....
Four-Year RUBY Data Support Curative Intent With Dostarlimab in dMMR/MSI-H Endometrial Cancer
Four-year follow-up from the phase III RUBY clinical trial showed durable long-term benefit with front-line dostarlimab-gxly, a PD-1 blocker, plus carboplatin/paclitaxel in patients with mismatch repair–deficient/microsatellite instability–high (dMMR/MSI-H) primary advanced or recurrent endometrial ...
Society of Gynecological Oncology Names 2026 President Matthew A. Powell, MD
Matthew A. Powell, MD, assumed the position of President of the Society of Gynecological Oncology (SGO) at the conclusion of the 2026 SGO Annual Meeting. Dr. Powell is the Ira C. and Judith Gall Distinguished Professor, Division of Gynecologic On-cology at Washington University School of Medicine...
Off-the-Shelf CAR T-Cell Therapy Produces Deep, Durable Responses in Heavily Pretreated Multiple Myeloma
CB-011, the first allogeneic anti-BCMA chimeric antigen receptor (CAR) T-cell therapy incorporating immune cloaking, achieved a high overall response rate in heavily pretreated patients with relapsed or refractory multiple myeloma in the phase I CaMMouflage trial. Dose-escalation results were...
Early Study Finds Intralesional PD-1 Blockade ‘Promising’ for Oral Cancer Prevention
Intralesional nivolumab reduced the size of precancerous lesions and preserved quality of life in patients with oral epithelial dysplasia, according to results from a first-in-human phase I dose-escalation trial presented in a poster and press briefing during the 2026 American Association for...
Losing Weight, Gaining Quality of Life in Early-Stage Breast Cancer
A telephone-based weight loss intervention improved physical function and other patient-reported outcomes among women with early-stage breast cancer and overweight or obesity, according to findings from the health outcomes (HO)-1 substudy of the phase III Breast Cancer WEight Loss (BWEL) trial...
Geriatric Assessment Is the Future: Retiring Karnofsky and ECOG Performance Status in Modern Cancer Care
The purpose of this editorial is to challenge the continued reliance on Karnofsky Performance Status and Eastern Cooperative Oncology Group (ECOG) or Zubrod performance status as primary tools for evaluating older adults with cancer. These measures have been in oncology practice for decades and...
A Burning Question: Can Wildfire Smoke Drive Cancer Risk?
Exposure to wildfire smoke was associated with significantly elevated risks of several cancers, including lung, colorectal, breast, bladder, and blood cancers, according to evidence from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial presented in a poster and press...
Weighing the Evidence Supporting Aspirin vs GLP-1RAs in Colorectal Cancer Prevention
A study by Jones et al offers a provocative contribution to the landscape of colorectal cancerprevention by directly comparing two pharmacologic strategies with markedly different historical roles in prevention (see sidebar on page 47).1 Aspirin has long served as the benchmark for primary...
Head-to-Head on Headspace: Cognitive Effects of Darolutamide vs Enzalutamide in Advanced Prostate Cancer
Patients with advanced prostate cancer treated with darolutamide experienced significantly less objectively assessed cognitive decline over 24 weeks than those receiving enzalutamide, according to results from the prospective, randomized open-label phase II ARACOG (AFT-47) trial to be presented at...
Short-Term Fasting Around Chemotherapy May Improve Treatment Response in Ovarian Cancer
Short-term fasting before and after chemotherapy reduced insulin levels and was associated with improved treatment response in patients with high-grade serous ovarian cancer, according to results of a two-arm pilot randomized trial presented at the 2026 ASCO Annual Meeting (Abstract 5517).1...
Review of Breast Cancer News and Studies
Among the high-quality abstract presentations at ASCO and the San Antonio Breast Cancer Symposium (SABCS), a few always stand out as particularly meritorious. The ASCO Post asked its Senior Deputy Editor, breast cancer specialist Jame Abraham, MD, FACP, to offer his selection and thoughts on some...
Daraxonrasib in KRAS-Mutant Pancreatic Cancer: A First Step in Shifting the Paradigm of Treatment
Wolpin and colleagues have demonstrated in the global randomized Phase III RASolute 302 trial that daraxonrasib, an oral RAS(ON) inhibitor, nearly doubles median overall survival in previously treated metastatic pancreatic ductal adenocarcinoma, producing a median overall survival of 13.2 months...
Can Psychostimulants Treat Cancer-Related Fatigue?
A new meta-analysis provides updated evidence that methylphenidate-type psychostimulants—a class of medications that increase dopamine and norepinephrine availability in the brain—can provide meaningful relief for cancer-related fatigue. The study was published in the May 2026 issue of...
‘The Science and Practice of Translation: Improving Cancer Outcomes Worldwide’
“Good morning, and welcome to the 62nd Annual Meeting of ASCO! ¡Buenos días, y bienvenidos a la sexagésima segunda reunión anual de ASCO! This is the world’s largest cancer research conference and the premier global platform for oncology innovation! But what brings us together today is not just...
How Cannabis Use May Be Accelerating Breast and Testicular Cancer Rates in AYAs
As the data continue to show, the incidence of breast, testis, and other cancers are on the rise in adolescent and young adults (AYAs) between the ages of 15 and 39, with increases of 30% over the last 4 decades.1 And while potential explanations for this rapid increase have included obesity,...
Another Point of View: Reefer Madness!
The conclusions drawn from the study by Johnson et al1 appear overstated and should be interpreted with caution. In the study discussed in this issue of The ASCO Post, investigators compared breast and testicular cancer incidence trends in American states that had or had not legalized the use of...
Expanded Living Guidelines Program Ushers in a New Era for ASCO Guidelines
ASCO initiated its guideline program in 1993 and published the first guideline on colony stimulating factors in 1994.1 ASCO has evolved from publishing one or two guidelines annually to maintaining a robust library of over 118 guidelines with new guidelines added annually. Today, ASCO publishes...
ASCO Updates Policy Statement on 340B Drug Pricing Program
Early last month ASCO published an updated policy statement on the 340B Drug Pricing Program in JCO Oncology Practice.1
The update proposes a package of recommendations to expand practice eligibility, address potential abuses, and ensure the 340B program benefits the patients it was intended to...
ASCO Welcomes Proposal to Implement Electronic Prior Authorization Requirements for Covered Drugs in Federal Health Plans
The Centers for Medicare & Medicaid Services (CMS) has issued the 2026 CMS Interoperability Standards and Prior Authorization for Drugs proposed rule. The proposal aims to shorten care delays and improve transparency within federal health insurance programs by establishing electronic prior...
2026 ASCO Breakthrough Meeting to Highlight New Advances in Liquid Biopsy, Metabolic Risks, and Tailored Therapies for Asian Populations
The ASCO Breakthrough meeting being held in Singapore this month will bring together global oncology professionals in Asia to discuss the latest cancer research advances across multiple disease sites that are shaping the future of patient care. New studies featured in the official Press Program...
Physician-Scientist Albert B. Deisseroth, MD, PhD Dies at 84
Albert B. Deisseroth, MD, PhD, of Potomac, Maryland, passed away November 6, 2025, at Suburban Hospital in Bethesda, Maryland.
Albert B. Deisseroth was born in 1941 in Middletown, New York. He attended the University of Rochester in New York where he earned his Bachelor’s degree. He stayed in...
Yoga Intervention May Reduce Mood Disturbance, Anxiety, Fatigue, and Insomnia in Cancer Survivors
A 4-week structured yoga intervention program named Yoga for Cancer Survivors (YOCAS) improved overall mood disturbance, anxiety, and fatigue among cancer survivors, according to findings from a phase III randomized controlled trial presented at the 2026 ASCO Annual Meeting (Abstract 12004).1 The...
How New York City—and the Nation—Got Its First Cancer Hospitals
Editor’s Note: On May 1, 2026, The New York Historical, an American history museum and library in New York City, published the following blog post by Leland Jasperse, PhD, in its From the Stacks collection. The story, “How New York City—and the Nation—Got Its First Cancer Hospitals,” chronicles the ...
Music Therapy Noninferior to Cognitive Behavioral Therapy for Anxiety Among Cancer Survivors in Large Telehealth Trial
Guest Editor’s Note: Anxiety is a troubling symptom for many cancer survivors, yet treatment options remain limited. Although cognitive behavioral therapy (CBT) can be beneficial, barriers to access may limit its use. Music therapy, a nonpharmacologic intervention, has been shown to be effective in ...
Advancing Clinical Trials and Decision-Making With Synthetic Real-World Data
Synthetic real-world data generated by AI can model treatment patterns and clinical outcomes across large patient cohorts while accelerating clinical trials and drug development, according to Eddy Saad, MD, MSc, a Research Fellow in Medicine at Dana-Farber Cancer Institute.
During a presentation...
Prostate Cancer Screening Controversies
We read with interest the recent commentary by Derek Raghavan, MD, PhD, FACP, FASCO, FRACP, on ‘Prostate Screening Saved My Life’ Is That Really True in Most Cases?’ (The ASCO Post, April 25, 2026).1 As patient advocates, we agree with Dr. Raghavan on one important point: simplistic claims such as...
‘I’d Like to Agree With You…But Then We Would Both Be Wrong’
I am pleased to respond to the Letter to the Editor from Davis and Wolinsky printed in this issue of The ASCO Post, disagreeing with my views about screening for prostate cancer.In brief, the key points of my commentary were as follows:
I’ve Beaten the Odds for Stage IV Lung Cancer
I learned that I had advanced stage non-small cell lung cancer (NSCLC) soon after a physician in the emergency department handed me the results of a computed tomography (CT) scan, which showed that I had lesions on my L3 and L4 vertebrae. The report stated that these lesions “were highly concerning ...
Coming Out in the Exam Room
Preparing for a patient I was going to see in breast oncology clinic, I noticed she was single and that her partner was female. The information system at the hospital I was working in included a patient photograph along with the usual demographic and clinical information. The photograph had caught ...
